Evidence map›Paper›PMID 28739794›Full record

Trial reportAntimicrobial agents and chemotherapy2017

Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Abdullah Alsultan, Jennifer J Furin, Jeannine Du Bois, Elana van Brakel, Phalkun Chheng, Amour Venter, Bonnie Thiel, Sara A Debanne, W Henry Boom, Andreas H Diacon and 2 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01516203 (Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01516203 phase2completednot on this map

Randomized, Open Label, Multiple Dose Phase 2a Study of the Early Bactericidal Activity of AZD5847 in Adults With Pulmonary Tuberculosis

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2012 to 2013Enrolled75ConditionsTuberculosisArmsAZD5847, Ethambutol, isoniazid, pyrazinamide, rifampin
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Abdullah AlsultanKing Saud University College of Pharmacy, Riyadh, Saudi Arabia.
Jennifer J FurinTuberculosis Research Unit, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Jeannine Du BoisTASK Applied Science, Cape Town, South Africa.
Elana van BrakelTASK Applied Science, Cape Town, South Africa.
Phalkun ChhengTuberculosis Research Unit, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Amour VenterMRC Centre for Tuberculosis Research, Tygerberg, South Africa.
Bonnie ThielTuberculosis Research Unit, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Sara A DebanneDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio, USA.
W Henry BoomTuberculosis Research Unit, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Andreas H DiaconTASK Applied Science, Cape Town, South Africa.
John L JohnsonTuberculosis Research Unit, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Charles A PeloquinUniversity of Florida College of Pharmacy, Gainesville, Florida, USA peloquin@cop.ufl.edu.
University Hospitals of Cleveland · USTask Applied Science · ZACase Western Reserve University · USFlorida College · USTygerberg Hospital · ZAUniversity of Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AZD-5847 is a new oxazolidinone derivative under development for the treatment of tuberculosis (TB). Here we describe the population pharmacokinetics (PK) of AZD-5847 in patients with tuberculosis based on a recently completed phase II study. The study included 60 patients with drug-susceptible TB. Patients were randomized to four dosages (500 mg once daily, 1,200 mg once daily, 500 mg twice daily, and 800 mg twice daily). Patients were intensively sampled on days 1 and 14. AZD-5847 pharmacokinetics were best described with a two-compartment model with lag time (

Indexed as

AdolescentAdultAgedAntitubercular AgentsBiological AvailabilityFemaleHumansLinezolidMaleMicrobial Sensitivity TestsMiddle AgedOxazolidinonesTuberculosis, PulmonaryYoung AdultAntitubercular AgentsLinezolidOxazolidinonesPNU-100480posizolidAZD-5847pharmacokineticstuberculosis

Identifiers

PMID28739794
PMCPMC5610519
OpenAlexW2738456084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.